Korkmaz, NesrinKisa, DursunKaplan, OzlemTosun, Nazan GoksenOzgur, AykutImamoglu, RizvanKaradag, Ahmet2026-01-242026-01-2420231612-18721612-1880https://doi.org/10.1002/cbdv.202300038https://hdl.handle.net/20.500.12868/5447This study investigated the biological activity of the silver coordination compound K-22. The IC50 values of K-22 on cancer cell lines range from 0.797 mu g/mL to 3.426 mu g/mL, indicating that K-22 might preferably inhibit A549, Saos-2, MCF-7, and HT-29 cell proliferation and thus have better therapeutic activity. Furthermore, K-22 stimulated apoptosis via up-regulation of the mRNA and protein expression level of Bax/Bcl-2 ratio in A549, Saos-2, MCF-7, and HT-29. K-22 exhibited antimicrobial activity against S. aureus, E. faecalis, K. pneumonia, P. aeruginosa, C. utilis, and C. albicans. Experimental results show that the compound has inhibitory potential with an IC50 value of 178.10 mu M for the BChE (butyrylcholinesterase) enzyme, which has a vital role in the progression of Alzheimer's disease. As a result, compound K-22 exhibits a strong potential for medical use due to its anticancer, antibacterial, antifungal, and anti-Alzheimer properties.eninfo:eu-repo/semantics/closedAccesscoordination compoundantimicrobial agentsanticancer activityanti-Alzheimer's compoundArticle10.1002/cbdv.202300038206371160902-s2.0-85159646120Q3WOS:000991464700001Q3